Abstract
Cancer of unknown primary site (CUP) has frustrated patients, their families and physicians for decades because appropriate therapies for patients with metastatic cancers are determined by the primary site or the tissue of origin. Now that we have methods to identify the tissue of origin for the majority of these patients, additional clinical and biological questions are being asked and addressed.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
The Potential Clinical and Economic Value of Primary Tumour Identification in Metastatic Cancer of Unknown Primary Tumour: A Population-Based Retrospective Matched Cohort Study
PharmacoEconomics - Open Open Access 06 September 2017
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Greco, F. A. & Hainsworth, J. D. in Cancer: Principles and Practice of Oncology (eds DeVita, V. T. Jr et al.) 9th edn 2033–2051 (Lippincott, Williams and Wilkins, 2011).
Pentheroudakis, G., Golfinopoulos, V. & Pavlidis, N. Switching benchmarks in cancer of unknown primary: from autopsy to microarray. Eur. J. Cancer. 43, 2026–2032 (2007).
Greco, F. A. The impact of molecular testing on treatment of cancer of unknown primary origin. Oncology (Williston Park) 27, 815–817 (2013).
Greco, F. A. Molecular diagnosis of the tissue of origin in cancer of unknown primary site: useful in patient management. Curr. Treat Options Oncol. http://dx.doi.org/10.1007/s11864-013-0257-1 (2013).
Greco, F. A. et al. Molecular profiling diagnosis in unknown primary cancer: accuracy and ability to complement standard pathology. J. Natl Cancer Inst. 105, 782–790 (2013).
Schwartz, A. M. & Harpaz, N. J. A primary approach to cancers of unknown primary. J. Natl Cancer Inst. 105, 759–761 (2013).
Hainsworth, J. D. et al. Molecular gene expression profiling to predict the tissue of origin and direct site-specific therapy in patients with carcinoma of unknown primary site: a prospective trial of the Sarah Cannon Research Institute. J. Clin. Oncol. 31, 217–223 (2013).
DePalma, M. & Hanahan, D. The biology of personalized cancer medicine: facing individual complexities underlying hallmark capabilities. Mol. Oncol. 6, 111–127 (2012).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Greco, F. Cancer of unknown primary site: still an entity, a biological mystery and a metastatic model. Nat Rev Cancer 14, 3–4 (2014). https://doi.org/10.1038/nrc3646
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrc3646
This article is cited by
-
The Potential Clinical and Economic Value of Primary Tumour Identification in Metastatic Cancer of Unknown Primary Tumour: A Population-Based Retrospective Matched Cohort Study
PharmacoEconomics - Open (2018)
-
Cancer research in need of a scientific revolution: Using ‘paradigm shift’ as a method of investigation
Journal of Biosciences (2015)